Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients

Neuropsychopharmacology

Volumn 33, Issue 10, 2008, Pages 2435-2441

  Erritzoe, David ^a   Rasmussen, Hans ^b   Kristiansen, Klaus T ^b   Frokjaer, Vibe G ^a   Haugbol, Steven ^a   Pinborg, Lars ^a   Baaré, William ^c   Svarer, Claus ^a   Madsen, Jacob ^a   Lublin, Henrik ^b   Knudsen, Gitte M ^a   Glenthoj, Birte Y ^b  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

Author keywords

5 HT2A receptor; Molecular imaging; PET; Positron emission tomography; Schizophrenia; Serotonin

Indexed keywords

ALTANSERIN; ALTANSERIN F 18; FLUORINE 18; RADIOLIGAND; SEROTONIN 2A RECEPTOR; TRACER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN CORTEX; BRAIN REGION; CAUDATE NUCLEUS; CEREBELLUM; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MENTAL PATIENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BINDING, COMPETITIVE; BRAIN; BRAIN CHEMISTRY; BRAIN MAPPING; CAUDATE NUCLEUS; CEREBRAL CORTEX; FEMALE; HUMANS; KETANSERIN; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, SEROTONIN, 5-HT2A; SCHIZOPHRENIA; SEROTONIN; SEROTONIN ANTAGONISTS; YOUNG ADULT;

EID: 49549118726     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301656     Document Type: Article

References (51)

1. Abdolmaleky HM, Faraone SV, Glatt SJ, Tsuang MT (2004). Meta-analysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia. Schizophr Res 67: 53-62.
2. Abi-Dargham A, Laruelle M, Aghajanian GK, Charney D, Krystal J (1997). The role of serotonin in the pathophysiology and treatment of schizophrenia. J Neuropsychiatry Clin Neurosci 9: 1-17.
3. Adams KH, Pinborg LH, Svarer C, Hasselbalch SG, Holm S, Haugbøl S et al (2004). A database of [(18)F]-altanserin binding to 5-HT(2A) receptors in normal volunteers: normative data and relationship to physiological and demographic variables. NeuroImage 21: 1105-1113.
4. Adams KH, Hansen ES, Pinborg LH, Hasselbalch SG, Svarer C, Holm S et al (2005). Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. Int J Neuropsychopharmacol 3: 391-401.
5. Arora RC, Meltzer HY (1991). Serotonin2 (5-HT2) receptor binding in frontal cortex of schizophrenic patients. J Neural Transm 85: 19-29.
6. Arranz MJ, Munro J, Owen MJ, Spurlock G, Sham PC, Zhao J et al (1998a). Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol Psychiatry 3: 61-66.
7. Arranz MJ, Munro J, Sham P, Kirov G, Murray RM, Collier DA et al (1998b). Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res 32: 93-99.
8. Bennett JP, Enna SJ, Bylund DB, Gillin JC, Wyatt RJ, Snyder SH (1979). Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry 36: 927-934.
9. Burnet PW, Eastwood SL, Harrison PJ (1996). 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 15: 442-455.
10. Dean B (2003). The cortical serotonin2A receptor and the pathology of schizophrenia: a likely accomplice. J Neurochem 85: 1-13.
11. Dean B, Hayes W (1996). Decreased frontal cortical serotonin2A receptors in schizophrenia. Schizophr Res 21: 133-139.
12. Dean B, Hayes W, Hill C, Copolov D (1998). Decreased serotonin2A receptors in Brodmann's area 9 from schizophrenic subjects. A pathological or pharmacological phenomenon? Mol Chem Neuropathol 34: 133-145.
13. Dean B, Hayes W, Opeskin K, Naylor L, Pavey G, Hill C et al (1996). Serotonin2 receptors and the serotonin transporter in the schizophrenic brain. Behav Brain Res 73: 169-175.
14. Dean B, Hussain T, Hayes W, Scarr E, Kitsoulis S, Hill C et al (1999). Changes in serotonin2A and GABA(A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex. J Neurochem 72: 1593-1599.
15. Denys D, Fineberg N, Carey PD, Stein DJ (2007). Quetiapine addition in obsessive-compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors? Biol Psychiatry 61: 412-414.
16. Gaddum JH (1954). Drug antagonistic to 5-hydroxytryptamine. In: Wolstenholme GW (ed). Ciba Foundation Symposium on Hypertension. Little Brown and Company: Boston, pp 75-77.
17. Glenthoj BY, Mackeprang T, Bille AE, Hemmingsen RP (1999). [Transmitter dysfunction in patients with schizophrenia. Significance for cognitive functioning and treatment]. Ugeskr Laeger 161: 1391-1398.
18. Gray JA, Roth BL (2001). Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull 56: 441-451.
19. Gurevich EV, Joyce JN (1997). Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol Psychiatry 42: 529-545.
20. Haugbøl S, Pinborg LH, Arfan HM, Frøkjær VM, Madsen J, Dyrby TB et al (2007). Reproducibility of 5-HT(2A) receptor measurements and sample size estimations with [(18)F]altanserin PET using a bolus/infusion approach. Eur J Nucl Med Mol Imaging 34: 910-915.
21. Hurlemann R, Boy C, Meyer PT, Scherk H, Wagner M, Herzog H et al (2005). Decreased prefrontal 5-HT2A receptor binding in subjects at enhanced risk for schizophrenia. Anat Embryol (Berl) 210: 519-523.
22. Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE (1993). Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 8: 315-336.
23. Kayahan B, Ozturk O, Veznedaroglu B (2005a). Obsessive-compulsive symptoms in schizophrenia. Turk Psikiyatri Derg 16: 205-215.
24. Kayahan B, Ozturk O, Veznedaroglu B, Eraslan D (2005b). Obsessive-compulsive symptoms in schizophrenia: prevalence and clinical correlates. Psychiatry Clin Neurosci 59: 291-295.
25. Kristiansen H, Elfving B, Plenge P, Pinborg LH, Gillings N, Knudsen GM (2005). Binding characteristics of the 5-HT2A receptor antagonists altanserin and MDL 100907. Synapse 58: 249-257.
26. Laruelle M, Abi-Dargham A, Casanova MF, Toti R, Weinberger DR, Kleinman JE (1993). Selective abnormalities of prefrontal serotonergic receptors in schizophrenia: a postmortem study. Arch Gen Psychiatry 50: 810-818.
27. Lemaire C, Cantineau R, Guillaume M, Plenevaux A, Christiaens L (1991). Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. J Nucl Med 32: 2266-2272.
28. 18F]setoperone in neuroleptic-naive patients and normal subjects. Am J Psychiatry 156: 72-78.
29. Masellis M, Basile V, Meltzer HY, Lieberman JA, Sevy S, Macciardi FM et al (1998). Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 19: 123-132.
30. Matsumoto I, Inoue Y, Iwazaki T, Pavey G, Dean B (2005). 5-HT2A and muscarinic receptors in schizophrenia: a postmortem study. Neurosci Lett 379: 164-168.
31. Meltzer H, Matsubara S, Lee J (1989). Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2, and serotonin2 pki values. J Pharmacol Exp Ther 251: 238-246.
32. Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003). Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27: 1159-1172.
33. Mita T, Hanada S, Nishino N, Kuno T, Nakai H, Yamadori T et al (1986). Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol Psychiatry 21: 1407-1414.
34. Ngan ET, Yatham LN, Ruth TJ, Liddle PF (2000). Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: a PET study using [(18)F]setoperone. Am J Psychiatry 157: 1016-1018.
35. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O et al (2000). Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography. Life Sci 66: 2455-2464.
36. 2A receptor binding correlates with lifetime aggression in suicide. Biol Psychiatry 59: 235-243.
37. 18F]altanserin-PET and the bolus/ infusion approach. J Cereb Blood Flow Metab 23: 985-996.
38. Pralong D, Tomaskovic-Crook E, Opeskin K, Copolov D, Dean B (2000). Serotonin(2A) receptors are reduced in the planum temporale from subjects with schizophrenia. Schizophr Res 44: 35-45.
39. Quarantelli M, Berkouk K, Prinster A, Landeau B, Svarer C, Balkay L et al (2004). Integrated software for the analysis of brain PET/ SPECT studies with partial-volume-effect correction. J Nucl Med 45: 192-201.
40. 2 receptors and their involvement in schizophrenia and neuroleptic drug action. J Neural Transm Suppl 18: 273-277.
41. Skapinakis P, Papatheodorou T, Mavreas V (2007). Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol 17: 79-93.
42. Sled JG, Zijdenbos AP, Evans AC (1998). A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 17: 87-97.
43. Svarer C, Madsen K, Hasselbalch SG, Pinborg LH, Haugbøl S, Froekjaer VG et al (2005). MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. NeuroImage 24: 969-979.
44. Svensson TH, Mathe JM, Andersson JL, Nomikos GG, Hildebrand BE, Marcus M (1995). Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism. J Clin Psychopharmacol 15: 11S-18S.
45. 18F]altanserin in human and rodent. Nucl Med Biol 26: 601-608.
46. Trichard C, Paillere-Martinot ML, Attar-Levy D, Blin J, Feline A, Martinot JL (1998). No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET. Schizophr Res 31: 13-17.
47. 18F]setoperone PET data shows no substantial serotonin 5-HT(2A) receptor changes in schizophrenia. Psychiatry Res 99: 123-135.
48. 123I] iomazenil. Eur J Pharmacol 249: 43-51.
49. Whitaker PM, Crow TJ, Ferrier IN (1981). Tritiated LSD binding in frontal cortex in schizophrenia. Arch Gen Psychiatry 38: 278-280.
50. Willendrup P, Pinborg LH, Hasselbalch SG, Adams KH, Stahr K, Knudsen GM et al (2004). Assessment of the precision in co-registration of structural MR-images and PET-images with localized binding. Int Congr Ser 275-280. ISBN: 0444515674.
51. Zhang W, Bymaster FP (1999). The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology (Berl) 141: 267-278.